<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR1800015885</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2018-04-26</date_registration>
      <primary_sponsor>Department of hematology, Xinqiao hospital, Army Medical University</primary_sponsor>
      <public_title>Clinical study on the maintenance treatment with chidamide for T- cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation</public_title>
      <acronym />
      <scientific_title>Effect on mintenance treatment with chidamide for T- cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantationï¼š A I/II phase, prospective, single center, open lable study.</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2018-05-01</date_enrolment>
      <type_enrolment />
      <target_size>Case series:47;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=27017</url>
      <study_type>Observational study</study_type>
      <study_design>Case series</study_design>
      <phase>I+II (Phase I+Phase II)</phase>
      <hc_freetext>T-cell acute lymphoblastic leukemia </hc_freetext>
      <i_freetext>Case series:chidamide;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Zhang  Cheng</firstname>
        <middlename />
        <lastname />
        <address>83 Xinqiao Main Street, Shapingba District, Chongqing, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 023-68774209</telephone>
        <email>chzhang2014@163.com</email>
        <affiliation>Department of hematology, Xinqiao hospital, Army Medical University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Zhang Cheng</firstname>
        <middlename />
        <lastname />
        <address>83 Xinqiao Main Street, Shapingba District, Chongqing, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 023-687774209</telephone>
        <email>chzhang2014@163.com</email>
        <affiliation>Department of hematology, Xinqiao hospital, Army Medical University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. The patients with T-cell acute lymphoblastic leukemia undergone allogeneic hematopoietic stem cell transplantation after inducion therapy and 2-cycle intensive treatment with high dose methotrexate;
2. The hematopoietic reconstitution is stable at day 30 to 45 after allogeneic hematopoietic stem cell transplantation and the acute lymphoblastic leukemia is complete remission;
3. The patients age 14 to 55 year old, and the KPS is over 60. The estimated survival is over three months;
4. The important organs are function,such as heart and brain.</inclusion_criteria>
      <agemin />
      <agemax />
      <gender>Both</gender>
      <exclusion_criteria>1. serious systemic organ dysfunction; 
2. Patient with malignant tumor that needs to be treat;
3. The patients with clinical symptom of brain dysfunction or serious psychiosis that can't understand or obey the study; 
4. Patients that can't followed up as scheduled.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>1-year disease-free survival;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>1-year oversurvival;1-year relapse rate;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Key clinical foundation of Xinqiao Hospital, Army Medical Univsesity</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-08-20</approval_date>
        <contact_name>Mina</contact_name>
        <contact_address>Chinese Clinical Trial Registry Hong Kong Center, Hong Kong Baptist University Road, Hong Kong SAR, China</contact_address>
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>